ARBUTUS BIOPHARMA CORP (ABUS)
CA03879J1003 - Common Stock
ABUS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. The financial health of ABUS is average, but there are quite some concerns on its profitability. ABUS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ABUS had negative earnings in the past year.
In the past year ABUS has reported a negative cash flow from operations.
ABUS had negative earnings in each of the past 5 years.
In the past 5 years ABUS always reported negative operating cash flow.
1.2 Ratios
ABUS's Return On Assets of -50.44% is in line compared to the rest of the industry. ABUS outperforms 49.32% of its industry peers.
ABUS has a Return On Equity (-68.71%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -50.44% | ||
| ROE | -68.71% | ||
| ROIC | N/A |
ROA(3y)-43.07%
ROA(5y)-68.17%
ROE(3y)-57.21%
ROE(5y)-94.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ABUS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ABUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ABUS has more shares outstanding
The number of shares outstanding for ABUS has been increased compared to 5 years ago.
There is no outstanding debt for ABUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -5.44, we must say that ABUS is in the distress zone and has some risk of bankruptcy.
ABUS has a Altman-Z score of -5.44. This is in the lower half of the industry: ABUS underperforms 64.33% of its industry peers.
ABUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.44 |
ROIC/WACCN/A
WACC9.31%
2.3 Liquidity
ABUS has a Current Ratio of 5.87. This indicates that ABUS is financially healthy and has no problem in meeting its short term obligations.
ABUS's Current ratio of 5.87 is fine compared to the rest of the industry. ABUS outperforms 61.43% of its industry peers.
A Quick Ratio of 5.87 indicates that ABUS has no problem at all paying its short term obligations.
ABUS has a Quick ratio of 5.87. This is in the better half of the industry: ABUS outperforms 62.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.87 | ||
| Quick Ratio | 5.87 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 6.57% over the past year.
The Revenue for ABUS has decreased by -53.50% in the past year. This is quite bad
The Revenue has been growing by 24.98% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)6.57%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q14.86%
Revenue 1Y (TTM)-53.5%
Revenue growth 3Y37.95%
Revenue growth 5Y24.98%
Revenue growth Q2Q-65.68%
3.2 Future
ABUS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.59% yearly.
ABUS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.78% yearly.
EPS Next Y-3.3%
EPS Next 2Y-10.84%
EPS Next 3Y-25.37%
EPS Next 5Y12.59%
Revenue Next Year-62.66%
Revenue Next 2Y-30.59%
Revenue Next 3Y-16.67%
Revenue Next 5Y26.78%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
ABUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ABUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ABUS's earnings are expected to decrease with -25.37% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.84%
EPS Next 3Y-25.37%
5. Dividend
5.1 Amount
No dividends for ABUS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARBUTUS BIOPHARMA CORP
NASDAQ:ABUS (4/26/2024, 7:00:00 PM)
Premarket: 2.71 -0.02 (-0.73%)2.73
+0.01 (+0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap491.86M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -50.44% | ||
| ROE | -68.71% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.87 | ||
| Quick Ratio | 5.87 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)6.57%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-3.3%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-53.5%
Revenue growth 3Y37.95%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y